Evolus, Inc. (EOLS)
USD 11.68
(3.96%)
USD 11.68
(3.96%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -49.23 Million USD | 37.29% |
| 2022 | -57.57 Million USD | 9.49% |
| 2021 | -63.61 Million USD | 7.4% |
| 2020 | -68.69 Million USD | 27.52% |
| 2019 | -94.78 Million USD | -105.42% |
| 2018 | -46.14 Million USD | -293.5% |
| 2017 | -11.72 Million USD | 41.27% |
| 2016 | -19.96 Million USD | 35.55% |
| 2015 | -30.98 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -7.34 Million USD | -44.51% |
| 2024 Q2 | -6.09 Million USD | 16.98% |
| 2023 Q4 | -5.08 Million USD | 62.19% |
| 2023 FY | -36.1 Million USD | 37.29% |
| 2023 Q1 | -10.39 Million USD | -17.72% |
| 2023 Q2 | -15.11 Million USD | -45.48% |
| 2023 Q3 | -13.44 Million USD | 11.1% |
| 2022 Q2 | -21.34 Million USD | -51.06% |
| 2022 Q1 | -14.13 Million USD | 21.66% |
| 2022 FY | -57.57 Million USD | 9.49% |
| 2022 Q4 | -8.82 Million USD | 47.08% |
| 2022 Q3 | -16.68 Million USD | 21.86% |
| 2021 FY | -63.61 Million USD | 7.4% |
| 2021 Q4 | -18.04 Million USD | 5.66% |
| 2021 Q1 | 8.01 Million USD | 107.42% |
| 2021 Q2 | -15.3 Million USD | -290.94% |
| 2021 Q3 | -19.12 Million USD | -24.96% |
| 2020 Q3 | -8.76 Million USD | 53.62% |
| 2020 FY | -68.69 Million USD | 27.52% |
| 2020 Q4 | -108.02 Million USD | -1133.17% |
| 2020 Q1 | -17.39 Million USD | -38.68% |
| 2020 Q2 | -18.88 Million USD | -8.58% |
| 2019 FY | -94.78 Million USD | -105.42% |
| 2019 Q4 | -12.54 Million USD | 50.1% |
| 2019 Q3 | -25.13 Million USD | 30.17% |
| 2019 Q2 | -35.99 Million USD | -42.46% |
| 2019 Q1 | -25.26 Million USD | -102.02% |
| 2018 Q3 | -11.48 Million USD | 28.64% |
| 2018 Q2 | -16.1 Million USD | -166.34% |
| 2018 Q4 | -12.5 Million USD | -8.87% |
| 2018 FY | -46.14 Million USD | -293.5% |
| 2018 Q1 | -6.04 Million USD | -111.51% |
| 2017 Q3 | -2.61 Million USD | -14.99% |
| 2017 FY | -11.72 Million USD | 41.27% |
| 2017 Q2 | -2.27 Million USD | 42.8% |
| 2017 Q4 | -2.85 Million USD | -9.25% |
| 2017 Q1 | -3.97 Million USD | -7.34% |
| 2016 FY | -19.96 Million USD | 35.55% |
| 2016 Q1 | -6.05 Million USD | 0.0% |
| 2016 Q2 | -6.05 Million USD | 0.0% |
| 2016 Q3 | -4.15 Million USD | 31.36% |
| 2016 Q4 | -3.7 Million USD | 10.83% |
| 2015 FY | -30.98 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 69.11% |
| PainReform Ltd. | -9.58 Million USD | -413.7% |
| Alvotech | -354.86 Million USD | 86.126% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 129.488% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 204.816% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -226.003% |
| Journey Medical Corporation | -2.07 Million USD | -2274.964% |
| Dynavax Technologies Corporation | -37.02 Million USD | -32.962% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 68.352% |
| Bright Green Corporation | -8.89 Million USD | -453.716% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 156.154% |
| Embecta Corp. | 221.5 Million USD | 122.227% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -928.839% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -928.839% |
| SCYNEXIS, Inc. | 72.66 Million USD | 167.75% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -261.546% |
| Silver Spike Investment Corp. | 7.34 Million USD | 770.739% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -1857.406% |
| Alpha Teknova, Inc. | -35.56 Million USD | -38.439% |
| Safety Shot Inc | -12.18 Million USD | -304.074% |
| Procaps Group, S.A. | 38.97 Million USD | 226.326% |
| Cosmos Health Inc. | -21.83 Million USD | -125.517% |
| Theratechnologies Inc. | -10.62 Million USD | -363.282% |
| Harrow Health, Inc. | 580 Thousand USD | 8588.448% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -947.288% |
| Biofrontera Inc. | -22.67 Million USD | -117.105% |
| DURECT Corporation | -36.88 Million USD | -33.481% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -834.39% |
| Cronos Group Inc. | -81.37 Million USD | 39.499% |
| OptiNose, Inc. | -22.74 Million USD | -116.428% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 123.552% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -25.745% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 489.748% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 493.078% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -1035.364% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -692.697% |
| Radius Health, Inc. | -3.92 Million USD | -1154.344% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -1295.978% |
| ProPhase Labs, Inc. | -21.61 Million USD | -127.793% |
| Phibro Animal Health Corporation | 53.31 Million USD | 192.344% |
| Procaps Group S.A. | 52.32 Million USD | 194.093% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -477.649% |
| Viatris Inc. | 766.2 Million USD | 106.426% |
| Rockwell Medical, Inc. | -6.67 Million USD | -638.126% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -837.057% |
| SIGA Technologies, Inc. | 83.62 Million USD | 158.876% |
| Tilray Brands, Inc. | -174.74 Million USD | 71.826% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 627.628% |
| Shineco, Inc. | -17.06 Million USD | -188.488% |
| PetIQ, Inc. | 60.01 Million USD | 182.034% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -939.389% |
| Incannex Healthcare Limited | -30.04 Million USD | -63.886% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 119.623% |
| Alimera Sciences, Inc. | -1.47 Million USD | -3246.907% |
| Assertio Holdings, Inc. | -243.53 Million USD | 79.784% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -735.537% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -215.718% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -145.55% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 64.285% |
| Hempacco Co., Inc. | -8.81 Million USD | -458.686% |
| Talphera, Inc. | -16.88 Million USD | -191.509% |
| Alvotech | -354.86 Million USD | 86.126% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 192.103% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 113.502% |
| Currenc Group, Inc. | -6.64 Million USD | -640.815% |
| Kamada Ltd. | 10.06 Million USD | 589.199% |
| Indivior PLC | -4 Million USD | -1130.825% |
| Evoke Pharma, Inc. | -7.43 Million USD | -562.545% |
| Flora Growth Corp. | -50.35 Million USD | 2.226% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -145.55% |
| HUTCHMED (China) Limited | 18.37 Million USD | 367.935% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 124.993% |
| Akanda Corp. | -10.05 Million USD | -389.814% |